Klugman K.P., Madhi S.A., Adegbola R.A., Cutts F., Greenwood B., Hausdorff W.P.
Respiratory and Meningeal Pathogens Research Unit, Medical Research Council, University of Witwatersrand, Johannesburg, South Africa; Rollins School of Public Health, Emory University, Atlanta, GA, United States; Bill and Melinda Gates Foundation, Seattle, WA, United States; London School of Tropical Medicine, United Kingdom; GSK Biologicals, Wavre, Belgium
Klugman, K.P., Respiratory and Meningeal Pathogens Research Unit, Medical Research Council, University of Witwatersrand, Johannesburg, South Africa, Rollins School of Public Health, Emory University, Atlanta, GA, United States; Madhi, S.A., Respiratory and Meningeal Pathogens Research Unit, Medical Research Council, University of Witwatersrand, Johannesburg, South Africa; Adegbola, R.A., Bill and Melinda Gates Foundation, Seattle, WA, United States; Cutts, F.; Greenwood, B., London School of Tropical Medicine, United Kingdom; Hausdorff, W.P., GSK Biologicals, Wavre, Belgium
Protection against serotype 1 could not be demonstrated in two randomized trials of 9 valent pneumococcal conjugate vaccines. An analysis of the timing of type 1 cases among vaccinees and controls shows that the vaccine failures occurred among cases occurring after the first year of life. Vaccination was given as three doses in infancy with no booster dose. These data suggest that a booster dose given at 9 months of age, or early in the second year of life, should be evaluated for protection against type 1 pneumococcal disease. © 2011 Elsevier Ltd.
Pneumococcus vaccine; article; booster dose; drug dose regimen; Gambia; human; infancy; invasive pneumococcal disease; opsonization; opsonophagocytic activity; pneumococcal infection; priority journal; serotype; South Africa; vaccine failure; Child, Preschool; Gambia; Humans; Immunization, Secondary; Infant; Pneumococcal Infections; Pneumococcal Vaccines; Randomized Controlled Trials as Topic; South Africa; Vaccines, Conjugate
